Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of "Buy" from Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have been assigned an average recommendation of "Buy" from the eight research firms that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $6.17.

Several research analysts recently issued reports on CNTX shares. D. Boral Capital reiterated a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Wednesday, April 9th. HC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Friday, March 21st. William Blair started coverage on Context Therapeutics in a research note on Monday. They issued an "outperform" rating for the company. JMP Securities started coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price target on the stock. Finally, Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. MPM Bioimpact LLC acquired a new stake in shares of Context Therapeutics in the 4th quarter valued at approximately $15,441,000. Franklin Resources Inc. increased its stake in Context Therapeutics by 115.9% in the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company's stock valued at $4,204,000 after purchasing an additional 2,149,392 shares in the last quarter. Allostery Investments LP bought a new stake in Context Therapeutics in the fourth quarter valued at approximately $998,000. Blue Owl Capital Holdings LP raised its holdings in Context Therapeutics by 17.5% in the fourth quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock worth $6,676,000 after purchasing an additional 946,638 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Context Therapeutics by 412.8% during the fourth quarter. Renaissance Technologies LLC now owns 338,435 shares of the company's stock worth $355,000 after purchasing an additional 272,435 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company's stock.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX traded up $0.00 during trading on Friday, reaching $0.94. The stock had a trading volume of 235,364 shares, compared to its average volume of 407,868. The stock has a market capitalization of $84.65 million, a PE ratio of -1.04 and a beta of 2.18. Context Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.75. The business's 50-day moving average price is $0.77 and its 200 day moving average price is $1.22.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. Analysts forecast that Context Therapeutics will post -0.51 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.